MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ygyno.2018.02.022

Медицинская библиотека · Gynecologic oncology · 2018

Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.

Tortorella Lucia, Langstraat Carrie L, Weaver Amy L, McGree Michaela E, Bakkum-Gamez Jamie N, Dowdy Sean C, Cliby William A, Keeney Gary L, Sherman Mark E, Weroha Saravut J, Mariani Andrea, Podratz Karl C

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Two randomized trials failed to demonstrate efficacy of platinum-based chemotherapy (PbCT) for uterine serous carcinoma (USC). Our objective was to reassess the value of PbCT for patients with microscopic residuum (R0).

METHODS

Progression-free survival (PFS) after surgery was analyzed for 409 patients and correlated with adjuvant therapies: vaginal brachytherapy (VBRT), external beam radiotherapy (EBRT), PbCT, or combinations.

RESULTS

The estimated 5-year PFS for stage I (n=209) USC was 65.1% for observation only; 90.7%, VBRT only; and 91.1%, PbCT±VBRT (85% received VBRT); VBRT significantly (P=.004) impacted PFS, but the added value of PbCT remains uncertain. Of 58 stage IIIC, PbCT-treated patients (±EBRT), 5-year PFS was 33.9%; most failures had a vascular disseminated component. Median PFS for 72 stage IV, PbCT-treated patients was 18.6months for R0; 8.0, R1≤1cm residual disease; and 4.6, R2>1cm (P=.008). The progression rate (PR) during 1 to 2year follow-up for R0 was similar to PR during 0-1year follow-up for R1 (P=.31), suggesting recurrences in patients with R0 disease before 2years are likely platinum resistant. PRs during follow-up were nearly identical for R0≥2years and R1≥1year (P=.95), presumably showing limited numbers of platinum-sensitive tumors.

CONCLUSIONS

A comparison of PR for patients treated with PbCT for stage IV R0 and R1 disease suggested that a 1-year lag interval precedes clinical recognition of PbCT refractory/resistant R0 disease. Most patients treated with PbCT who had microscopic residuum had recurrences within 2years (across stages), emphasizing the need for more effective therapy.

Для цитирования: Tortorella Lucia, Langstraat Carrie L, Weaver Amy L, McGree Michaela E, Bakkum-Gamez Jamie N, Dowdy Sean C, Cliby William A, Keeney Gary L, Sherman Mark E, Weroha Saravut J, Mariani Andrea, Podratz Karl C. Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.. Gynecologic oncology. 2018. DOI: 10.1016/j.ygyno.2018.02.022.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.